Narrative Review Explores Immune Checkpoint Inhibition in Pediatric Medulloblastoma

Photo by Faustina Okeke / Unsplash

Frontiers in Medicine Published May 9, 2026 Medically reviewed May 9, 2026 Study authors: Rachel L. Welch, Kirsten Moziak, Xingxing Zang, Allison M. Martin DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider immune checkpoint inhibition for pediatric medulloblastoma as experimental; evidence is preliminary and limited.

This narrative review examines the role of immune checkpoint inhibition, specifically through direct antibody targeting, in pediatric patients with medulloblastoma. The authors discuss the biological rationale for this approach, including the expression of immune checkpoints in the tumor microenvironment, and summarize available preclinical and early clinical data. While some studies suggest potential antitumor activity, the evidence is limited and heterogeneous, with no pooled effect sizes reported.

Key challenges identified include the immunosuppressive nature of medulloblastoma, limited tumor mutational burden, and the blood-brain barrier, which may restrict antibody penetration. The review also notes the lack of robust clinical trial data in children, with most evidence extrapolated from adult brain tumors or preclinical models.

The authors do not report specific safety data, adverse events, or tolerability outcomes, reflecting the early stage of investigation. Limitations include the narrative format, which may introduce selection bias, and the absence of systematic literature search methods.

For clinicians, this review underscores that immune checkpoint inhibition for pediatric medulloblastoma remains experimental. While the concept is biologically plausible, there is insufficient evidence to support routine clinical use. Further research, including well-designed clinical trials, is needed to establish efficacy and safety in this population.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Medulloblastoma (MB) is the most common pediatric embryonal tumor of the central nervous system. MB grows rapidly in the cerebellum and causes devastating disease in young children. The presence of high-risk molecular or histopathological features is associated with frequent recurrence, resistance to therapy, and poor prognosis, with few experiencing long-term survival. The current standard of care for MB includes surgical resection, radiation, and chemotherapy; however, there remains a need for more specific and effective treatment strategies, especially in recurrent disease. Promising developments in immune checkpoint inhibition have recently entered clinical trials, yet few address MB. Classic immune checkpoints such as Programmed Cell Death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) have recently been identified as potential therapeutic targets for slowing MB progression in the recurrent setting. Preclinical and clinical studies have identified additional targets such as B7-H3, V-domain Ig Suppressor of T-cell Activation (VISTA), lymphocyte-activated gene 3 (LAG-3), P-selectin glycoprotein 1 (PSGL-1), and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) expression in the MB TME. This review summarizes current preclinical and clinical prospects for immune checkpoint inhibition via direct antibody targeting for the treatment of MB and describes the proposed next generation of immune checkpoint inhibitors.